Incyte Corp (NASDAQ:INCY)

What a Combined Gilead and Incyte Would Look Like

Gilead Sciences Inc. (NASDAQ: GILD) has long been in need of a catalyst to move its business, and a lot of investors and analysts alike have considered this company dead ...
Read Full Story »
Profit or Loss

Top 5 Earnings to Look For on Tuesday

The most recent earnings season is coming to a close, and the broad markets are pushing even higher with the Dow, Nasdaq and S&P 500 hitting new highs within the ...
Read Full Story »
Handshake

Why This Collaboration Is So Important for Calithera

Shares of Calithera Biosciences Inc. (NASDAQ: CALA) saw a solid gain early on Monday after the company reported a global collaboration and licensing agreement with Incyte Corp. (NASDAQ: INCY). Ultimately, this ...
Read Full Story »
Good heart health

Why Credit Suisse Sees Incyte Rising Over 15%

Incyte Corp. (NASDAQ: INCY) is one of the health care stocks that hit it big in 2016 — that is, after it crashed and burned. As we all know, 2016 ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Ally, IBM, MetLife, Qualcomm, Verizon, Williams, Incyte and Many More

Stocks have pulled back off their highs from the end of 2016 and that Dow Jones Industrial Average (DJIA) 20,000 mark remains elusive. The major market indexes were indicated a ...
Read Full Story »
Test tubes

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

Needless to say, the past two years have been rough on biotech. So rough in fact, that a basket of the largest capitalization stocks now trades with a price-to-earnings growth ...
Read Full Story »
bigger fish

These 5 Biotech Stocks Could Be Big Takeover Targets in 2017

After a very tough year for the biotech stocks last year, they initially jumped after the election of Donald Trump as investors hoped that the rhetoric on drug pricing would ...
Read Full Story »
bigger fish

3 Biotech Stocks Could Be the Next Big Takeover Targets

Just as the biotech segment was starting to regain lost ground, and was fast approaching 2016 highs, yet another speed bump was hit. The EpiPen controversy, and the resulting commentary again ...
Read Full Story »
Doctor, Health (pulse) copy

Analysts Very Positive on 3 Top Stocks Following Jefferies Healthcare Conference

If it’s summertime then it is Wall Street conference time, because when the weather heats up so does the conference schedule. With the Jefferies Healthcare Conference wrapping up in New ...
Read Full Story »
graph

5 Biotechs With the Most Upside This Earnings Cycle

With earnings just around the corner, one key analyst is taking the opportunity to share its thoughts on select mid-cap and large-cap biotech companies. Despite a modest erosion to fundamentals and sector ...
Read Full Story »
biotech word cloud

8 Major Biopharma Events Coming Later in 2016 and in 2017

Companies in the pharmaceutical industry generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There can be a fair amount of risk ...
Read Full Story »
buy sell stocks

Top Analyst Upgrades and Downgrades: Schwab, Dean Foods, HollyFrontier, Incyte, Newfield Exploration, Nike and More

Stocks were looking for direction on Wednesday. With the S&P 500 and Dow going positive for the year just at the end of last week, investors now have to wonder ...
Read Full Story »
buy button

Massive Biotech Purchases Highlight Insider Buying: Incyte, TransDigm, Prospect Capital, Xenoport and More

Finally, after what seemed like the longest six weeks in history, the market staged at least a solid attempt to rally and restore investor confidence this past week. Firming oil ...
Read Full Story »
biotech word cloud

4 BioPharma Movers That Cannot Be Ignored

Over the past week, a few biotech companies made absolutely massive runs, either up and down. In the past year, the health care sector was on fire from positive trials, ...
Read Full Story »
coins

Incyte Underwhelms With Earnings

Incyte Corp. (NASDAQ: INCY) reported its fourth-quarter financial results after the markets closed on Wednesday. The company had $0.29 in earnings per share (EPS) on $243.88 million in revenue, which ...
Read Full Story »